Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Last-Minute Cancellation Of Advisory Panel Meeting Throws Future of Luveniq Into Doubt

This article was originally published in The Pink Sheet Daily

Executive Summary

"Several outstanding issues" forced FDA to cancel the meeting, the agency said.
Advertisement

Related Content

Advisory Panel For Bristol's Yervoy Is Called Off, Which May Bode Well
Advisory Panel For Bristol's Yervoy Is Called Off, Which May Bode Well
FDA Says Lux's Uveitis Treatment Luveniq Needs Another Clinical Trial
3SBio Signs Deal For Isotechnika's Transplant/Immune System Drug Voclosporin
FDA's NME Approval Rebound At Risk: Drought Of Novel Products In Line For Action In Remainder Of 2010 Could Depress Upward Trend From First Half
FDA Says Lux's Uveitis Treatment Luveniq Needs Another Clinical Trial
FDA's NME Approval Rebound At Risk: Drought Of Novel Products In Line For Action In Remainder Of 2010 Could Depress Upward Trend From First Half
Luveniq Advisory Committee: Renal Side Effects May Be Key Issue With Immunosuppressant
Luveniq Advisory Committee: Renal Side Effects May Be Key Issue With Immunosuppressant
Burned By Ketek, FDA Took Care With Possible Data Integrity Issues For Telavancin

Topics

Advertisement
UsernamePublicRestriction

Register

PS070802

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel